Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03302247 · ClinicalTrials.gov registry record · Phase 2
Depletion of Myeloid Derived Suppressor Cells to Enhance Anti PD-1 Therapy
A Phase 2 study, sponsored by Fox Chase Cancer Center.
- Terminated
- Registry status
- Phase 2
- Development phase
- 3
- Enrollment target
NCT03302247: Clinical Trial Phase 2 study, sponsored by Fox Chase Cancer Center.
NCT03302247 is a Phase 2 study that was terminated before completion, run by Fox Chase Cancer Center. The registered enrollment target is 3 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03302247, a Phase 2 study, was terminated before completion, sponsored by Fox Chase Cancer Center.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 3 participants
- Enrollment target
Study Summary
Metastatic non small cell lung cancer can be treated with cytotoxic chemotherapy or using recently approved immunotherapy with antibody, Nivolumab. Both the therapies have limitation due to development of tolerance or immunosuppression. This trial combines one drug from each category, immunotherapeutic Nivolumab and chemotherapeutic gemcitabine as it was reported that gemcitabine reduces immunosuppression by killing myeloid derived suppressor cells, thereby increasing the efficacy of Nivolumab.
Primary Outcome
Immunosuppression in terms of number of circulating MDSC in the blood by comparing within each arm reduction in the number of MDSCs after each cycle of treatment
Interventions
- BIOLOGICAL Nivolumab
- DRUG Nivolumab+Gemcitabine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2018-01-15 |
| Est. Completion | 2019-07-12 |
| Phase | Phase 2 |
Why NCT03302247 stopped before completion
NCT03302247 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 3 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 2 interventions - of which Nivolumab is the first listed.
NCT03302247 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03302247 about?
NCT03302247 is a clinical study titled "Depletion of Myeloid Derived Suppressor Cells to Enhance Anti PD-1 Therapy". Metastatic non small cell lung cancer can be treated with cytotoxic chemotherapy or using recently approved immunotherapy with antibody, Nivolumab. Both the therapies have limitation due to development of tolerance or immunosuppression. This trial combines one drug from each category, immunotherapeu...
What is the current status of trial NCT03302247?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 3 participants. The study started on 2018-01-15. Estimated completion is 2019-07-12.
What interventions are being tested in trial NCT03302247?
The interventions under investigation include: Nivolumab (BIOLOGICAL), Nivolumab+Gemcitabine (DRUG).
Who is sponsoring clinical trial NCT03302247?
This trial is sponsored by Fox Chase Cancer Center, which has 183 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03302247's enrollment target sits among peer trials
3 2001st of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI